

2011 Prohibited List Changes

The main changes to the List are as follows;

New on the Prohibited List

- A new category S0 has been introduced. It is prohibited to take any substances that are undergoing pre-clinical or clinical development and are therefore not officially allowed for human therapeutic use.
- Desmopressin as a masking agent is now included.

Sequential withdrawal, manipulation and reinfusion of whole blood into the circulatory system is prohibited.

The prohibition of the sequential withdrawal, manipulation, and reinfusion of whole blood is not intended to prevent blood donation processes, such as plasmapheresis - a specialised form of blood donation which does not involve the re-administration of whole blood.

Those undergoing hemodialysis, as part of the treatment of chronic kidney disease, will require a Therapeutic Use Exception (TUE) for such procedures.

http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Explanatory_Notes_Prohibited_List_EN.pdf

No longer on the Prohibited List

- A Declaration of Use is no longer required. This means that the following are not prohibited
 - salbutamol* and salmeterol by inhalation
 - glucocorticosteroids by inhalation
 - glucocorticosteroids administered by localised injection

*PLEASE NOTE: Salbutamol still has a threshold level of permitted use (maximum 1600 micrograms over 24 hours), and a TUE is required for Formoterol and Terbutelline.

The removal of the obligation for athletes to file a Declaration of Use for specific substances will help to reduce the administrative requirements surrounding anti-doping in 2011.

- Platelet derived preparations
Intramuscular route, local injections for treatment of tendon, muscle, bone and joint injuries are no longer prohibited.

Platelet-derived preparations have been removed from the List because of the lack of any current evidence concerning the use of these methods for performance enhancement.

Despite the presence of some growth factors, current studies on platelet derived preparations do not demonstrate any potential for performance enhancement beyond a potential therapeutic effect. Note that individual growth factors are still prohibited when given separately as purified substances as described in S.2.5

Category changes

- Methylhexanamine changes from a non-specified to a specified substance.

Clarification given

- IV infusion prohibited except for legitimate clinical investigation or hospital treatment.

Where the use of IV infusions falls outside a hospital admission or clinical investigation, then the attending physician in collaboration with at least one other independent colleague, must ensure that the criteria stipulated by WADA is met.

Intravenous injections are permitted if the injected substance is not prohibited, the volume does not exceed 50 mL, and the intravenous injections are given at intervals equal or greater than six hours.

Additional information can be found in the Medical Information on Intravenous Infusion, [http://www.wada-ama.org/Documents/Science Medicine/Medical info to support TUECs/WADA Medical info IV infusions v.2.2 March2010 EN.pdf](http://www.wada-ama.org/Documents/Science_Medicine/Medical_info_to_support_TUECs/WADA_Medical_info_IV_infusions_v.2.2_March2010_EN.pdf)

Should you have any questions about the changes please contact Amy Dyer at amy.dyer@ukad.org.uk or on 020 7766 350.